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A B S T R A C T
Purpose
We studied whether the risk of central venous catheter (CVC) –related thrombosis increased
after an episode of CVC-related infection in patients undergoing intensive chemotherapy.
Secondly, we determined whether thrombosis can be predicted or excluded by CVC lock
fluid surveillance cultures.
Patients and Methods
In a prospective setting, 105 consecutive patients were carefully examined for CVC-related
infection and thrombosis. In all patients, microbial surveillance cultures of CVC lock fluid
were taken every other day. All patients with clinical suspicion of CVC-related thrombosis
underwent Doppler ultrasound or additional venography.
Results
The cumulative incidence of CVC-related infection was 24% (25 of 105 patients). Clinically
manifest thrombosis occurred in 13 (12%) of 105 patients. In patients with CVC-related
infection, the risk of thrombosis increased markedly in comparison to those without infection
(relative risk, 17.6; 95% CI, 4.1 to 74.1). In patients having two or more positive subsequent
CVC lock fluid cultures with identical micro-organisms, 71.4% developed thrombosis, as
compared with 3.3% in patients with negative or a single positive culture.
Conclusion
The risk of clinically manifest thrombosis is increased after an episode of CVC-related
infection in patients undergoing intensive chemotherapy. Surveillance culturing of CVC lock
fluid may be clinically useful in estimating the risk for thrombosis and the instigation of
focused early intervention.
J Clin Oncol 23:2655-2660. © 2005 by American Society of Clinical Oncology
INTRODUCTION
In patients who undergo intensive chemo-
therapy or a stem-cell transplantation, cen-
tral venous access is often needed. The use of
a central venous catheter (CVC) may be
complicated by thrombosis and associated
complications such as pulmonary embo-
lism, which may lead to premature removal
of the CVC and anticoagulant treatment.1,2
These patients, who often suffer from
thrombocytopenia, are particularly vulnera-
ble for bleeding complications.
An association of CVC-related infec-
tion with CVC-related thrombosis has been
suggested previously.3-5 However, the re-
ported thrombotic events were subclinical
and were often diagnosed at CVC removal.
Whether CVC-related infection increases
the risk of clinically manifest thrombosis
while the CVC remains in place is unknown.
It is highly relevant to investigate this asso-
ciation since early determination and inter-
vention on the diagnosis of infection in
these patients could lead to CVC salvage and
may prevent thrombotic complications. We
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undertook a prospective study to evaluate whether, and
to what extent, CVC-related infection increases the risk
of subsequent clinically manifest thrombosis. In addition,
we assessed the predictive value of surveillance CVC lock
cultures in the diagnosis of thrombosis, which gives infor-
mation on the potential benefits of prevention of throm-
botic complications.
PATIENTS AND METHODS
Patients and Study Design
This study was performed at the department of Hematology
of the Leiden University Medical Center from October 2000 until
May 2002, a tertiary referral center for hematologic disease in the
Netherlands.6 The study protocol was approved by the local med-
ical ethical committee, and all participating patients gave written
informed consent. All consecutive patients 16 years or older with a
CVC inserted for over 48 hours were considered for enrollment.
CVCs were inserted via the subclavian or jugular vein and
were used for administering cytotoxic drugs and supporting treat-
ment (ie, fluids, blood products, parenteral feeding, and antimi-
crobial therapy). Nurses were allowed to withdraw blood from the
CVC for diagnostic purposes and monitoring. The lumina of the
CVC were rinsed daily with urokinase (3,750 U in 1.5 mL sodium
chloride). The use of urokinase for the prevention of CVC-related
complicationswas based on local experience (not yet published) as
well as other studies, the data of which suggest that urokinase may
reduce the risk of (serious) infectious CVC complication as com-
pared with heparin or saline alone.7,8 No antibiotic prophylaxis
specifically for CVC-related infections were given. All patients
were treated according to a local protocol to prevent infections
with aerobic Gram-negative rods, Viridans streptococci and Can-
dida spp.9 Prophylactic treatment included neomycin (250 mg),
polymyxin B (1.106U) orally qd, pipemidic acid 400mg orally bid,
and amphotericin B 200/10 mg qd. After 10 days of treatment, the
dosage of the regimewas reduced (half of the dosage inmg), except
for the pipemidic acid.
Patients with abnormal Doppler ultrasound findings (per-
formed within 48 hours after insertion) were excluded if they had
a previous CVC at the same insertion site or if they had a proven
thrombosis at the same insertion site. Patients who were unable to
undergo Doppler ultrasound were also excluded.
Microbiologic Surveillance and Treatment
Starting the day after the insertion of the CVC, lock fluid was
cultured routinely each second day as described previously.10 If a
surveillance CVC lock fluid culture yielded growth of micro-
organisms (positive lock culture), lock cultures were drawn daily.
At each episode of onset of fever (body temperature 38.5°C) or
other symptoms or signs of infection (hypotension, chills, hypo-
thermia, unexplained tachycardia), blood cultures were drawn, at
least one via the CVC and one by standard venipuncture. At least
two blood cultures were drawn on each consecutive day in all
patients with clinical symptoms or signs of infection, until a caus-
ativemicro-organismwas isolated. In the presence of clinical signs
of inflammation at the insertion site (ie, erythema, exudation,
tenderness, warmth, or swelling) swab cultures were taken. Cath-
eter tip cultures were not performed routinely, but only to support
the diagnosis of CVC-related infection. Micro-organisms were
identified by current tests (DNAse testing), additional commercial
ID 32 STAPH biochemical test strips (API; bioMerieux, Lyon,
France), and antimicrobial sensitivity patterns.
The criteria for establishing a diagnosis of CVC-related infec-
tion were adapted to previous studies.10,11 Two entities were dis-
tinguished: “local CVC infection” and “systemic CVC-related
infection” (Table 1).11
In case of a proven insertion site infection or CVC coloniza-
tion, appropriate antimicrobial therapy was started. The CVCwas
left in place. If a single CVC lock fluid culture was positive, no
treatment was started. In case of fever or other symptoms or signs
of systemic infection, empirical therapy was started (ceftazidime
500 mg intravenously tid and teicoplanin 200 mg intravenously
bid on day 1, qid on consecutive days). Empirical therapy was
discontinued if blood cultures remained negative after 72 hours. If
a systemic CVC-related septicemia was diagnosed, empirical ther-
apy was adjusted to the most appropriate small-spectrum regi-
men.7 The CVCs were not removed routinely.
Outcome: CVC-Related Thrombosis
During admission, all patients were routinely examined
each day for symptoms and signs of CVC-related thrombosis;
pain, swelling, discoloration, visible collateral circulation, or CVC
dysfunction. Discharged patients were seen once weekly at the
outpatient clinic by attending physicians. Patients with a clinical
suspicion of CVC-related thrombosis were referred to the depart-
ment of Radiology for Doppler ultrasound. If Doppler ultrasound
Table 1. Definitions of the Different Types of CVC-Related Infection Adapted to Earlier Studies
Descriptions
1. Local CVC infection
A. Insertion site infection: The CVC insertion site exhibits clinical signs of inflammation with the swab Gram stain  20 micro-organisms per field of
vision (1,000 ) and a positive culture within 48 hours. The CVC lock fluid and blood cultures remain negative.
B. Significant CVC colonization: At least two consecutive CVC lock cultures become positive within 48 hours or the CVC tip culture is positive.
Blood cultures by venipunture are negative; CVC drawn blood cultures may yield identical micro-organisms.
2. Systemic CVC-related infection
CVC-related bacteremia: Presence of fever (body temperature  38.5°C) or clinical signs or symptoms of infection, and blood cultures are positive.
The insertion-site swab, CVC tip culture, or a positive CVC lock culture yields growth of identical micro-organisms. A systemic CVC-associated
infection with positive blood cultures at least 24 hours after adequate antimicrobial therapy is considered as a major systemic CVC infection.
NOTE. Earlier studies include those by Guiot et al10 and Raad et al.11
Abbreviation: CVC, central venous catheter.
In case of coagulase-negative staphylococci, at least two drawn blood cultures are positive.
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findings appeared normal or were inconclusive, additional venog-
raphy was performed. In addition, for this study, all patients with
clinically suspected thrombosis were examined by an independent
examiner who performed Doppler ultrasound. These examina-
tions were coded and assessed by a panel of two blinded physicians
experienced in Doppler ultrasound evaluation. If needed, a third
expert opinionwas asked. A diagnosis of thrombosis wasmadewhen
Doppler ultrasound recordings were abnormal, or when normal or
inconclusive by an abnormal venogram. Follow-up for CVC-related
thrombosis took place until 6 weeks after CVC removal.
A diagnosis of CVC-related thrombosis was made according
to predefined criteria. For veins accessible to insonation, the crite-
ria of noncompressibility, visualization of echogenic intraluminal
mass, and absence of respiratory variation (jugular, axillary, or
subclavian vein) were used.12-15 For veins inaccessible to direct
insonation (middle part of the subclavian vein, brachiocephalic
vein, and superior caval vein), the criterion of monophasic flow to
detect occlusive thrombosis was used.16 A diagnosis of thrombosis
by contrast venogram was made in case of intraluminal filling
defects of a venous segment (axillary, subclavian, brachiocephalic,
or superior caval vein) or persistent nonfilling of a venous segment
in the presence of collateral circulation.17
Statistical Analysis
Cumulative incidences for infection and thrombosis were
calculated as number of first events over the number of individuals
at baseline, and Kaplan-Meier statistics were performed. Patients
were censored if they died or reached the end of follow-up. Rela-
tive risks (RR) and 95% CIs were calculated and based on SEs for
binominal distributions. The relation of infection and thrombosis
was assessed by applying Fisher’s exact test (P  .05 was consid-
ered statistically significant).
RESULTS
Patients and CVC-Related Thrombosis
The main patient and CVC characteristics have been
described in detail elsewhere.6 Briefly, of 136 consecutive
patients, 110 consented to participate. Two patients were ex-
cluded before the start of the study, and three patients were
excluded from the analysis based on exclusion criteria. Ulti-
mately, for 105 patients, complete data were obtained and
evaluated. The main characteristics for these 105 patients are
shown in Table 2. None of the pretreatment parameters in
Table 2 predisposed for CVC-related infection or thrombosis.
In 25 patients, CVC-related thrombosis was clinically
suspected on symptoms and signs. In 13 of these 25 patients,
clinically manifest thrombosis was objectified (cumulative
incidence, 12.4%; 95% CI, 6.1% to18.7%). In the other 12
patients, thrombosis was excluded by diagnostic imaging.
There was no disagreement between the real-time diagnosis
and the diagnosis as judged by our blinded panel.
CVC-Related Infection and Risk of Clinically
Manifest Thrombosis
The cumulative incidences for CVC-related infections
and the absolute and relative risks of subsequent clinically
manifest thrombosis are summarized in Table 3. Overall,
CVC-related infection was observed in 25 of 105 patients
(cumulative incidence, 23.8%; 95% CI, 15.7% to 32%). In
11 patients (10.5%) CVC-related infection was classified as
a local CVC infection such as CVC colonization (n 1), a
local insertion-site infection (n 6), or both (n 4) in the
absence of associated bacteraemia. Swab and CVC lock-
fluid cultures yielded mainly coagulase-negative staphylo-
cocci (CoNS; n 6) or multiple types of micro-organisms
including CoNS (n  3). Other isolated pathogens were
Enterobacter spp (n  1) and Acinetobacter spp (n  1).
Another 14 patients (13.3%; 95% CI, 6.8% to 19.8%) suf-
fered from systemic CVC-related infection. In these pa-
tients, blood cultures yieldedCoNS (n 10),multiple types
of micro-organisms including CoNS (n 3), and Coryne-
bacterium spp (n 1).
In the group of patients with a CVC-related infection,
the frequency of subsequent clinically manifest thrombosis
was 44% (11 of 25 patients), comparedwith 3% thrombosis
in the patients without CVC-related infection (two of 80
patients; P .05). This yields a relative risk of 17.6 (95%CI,
4.1 to 74.1). Our findings suggest that the absolute risk of
clinically manifest thrombosis increases with the severity of
infection since thrombosis was observed in 57.1% of pa-
tients with systemic CVC-related infection as compared
with 27.3% in patients with a local CVC infection (Table 3).
The frequency of CVC-related infection in the group of
patients with objectified CVC-related thrombosis was
Table 2. Baseline Characteristics of the Study Patients
No. of
Patients %
Age, years
Mean 48
Range 16-77
Central venous catheter in situ, days
Mean 22
Range 5-64
Sex
Male 63 60
Female 42 40
Disease
Acute myeloid leukemia 46 43.8
Acute lymphoblastic leukemia 13 12.4
Lymphoma 13 12.4
Chronic myeloid leukemia 11 10.5
Multiple myeloma 11 10.5
Other 11 10.5
Therapy
Intensive chemotherapy 48 45.7
Stem-cell transplantation
Allogeneic 36 34.2
Autologous 21 20
Central venous catheter
Double or trilumen 100 95.2
Subclavian vein 94 89.5
Left insertion side 71 67.7
Catheter-Related Infection and Thrombosis
www.jco.org 2657
Copyright © 2005 by the American Society of Clinical Oncology. All rights reserved. 
Information downloaded from www.jco.org and provided by WALAEUS LIBR on October 16, 2006 from 132.229.186.20. 
higher than in the group of patients in whom thrombosis
was clinically suspected but ruled out (84.6% v 16.7%),
indicating that the observed association of infection with
thrombosis was not affected by the knowledge of infection
among attending physicians who had decided on referral
for diagnostic imaging for thrombosis.
Fifteen patients had a systemic infection (14.3%; 95%
CI, 7.6% to 21%) classified as unrelated to the CVC. Blood
cultures in these patients yielded CoNS (n 4), Streptococ-
cus spp (n 3), multiple types ofmicro-organisms (n 3),
Candida albicans (n  2), or other micro-organisms (n 
3). Of these patients, only one suffered from clinically man-
ifest thrombosis (6.7%).
Accuracy for CVC Lock Fluid Cultures to Predict
Clinically Manifest Thrombosis
During follow-up, 30 of 105 patients had at least one
positive surveillance CVC lock culture (28.6%). Of 13 pa-
tients with clinically manifest thrombosis, 11 had at least
one prior positive culture (sensitivity, 84.6%; 95% CI, 65%
to 100%). In 73 of 92 patients without clinically manifest
thrombosis, a negative culture was obtained for a specificity
of 79.3% (95% CI, 71.1% to 87.6%). Of 75 patients with
serially negative CVC lock fluid cultures, thrombosis oc-
curred in two (negative predictive value 97.3%, 95% CI,
93.7% to 100%), whereas 11 of 30 patients with a positive
CVC lock fluid developed thrombosis (positive predictive
value, 36.7%; 95%CI, 19.4% to 53.9%). If two ormore subse-
quent positive cultures with identical strains of micro-
organisms were used to predict symptomatic thrombosis,
the positive predictive value increased to 71.4%, whereas the
negative predictive value decreased only slightly (96.7%). As
illustrated in Figure 1, the risk of thrombosis increased mark-
edly inpatientswith twoormoreconsecutivepositive cultures,
as compared with only one positive followed by negative cul-
tures or consecutive negative cultures.
The time interval between the first positive surveillance
culture and the clinical diagnosis in 11 patients with clini-
cally manifest thrombosis ranged from 1 to 39 days (mean,
9 days).
DISCUSSION
In the present study, we show a clear temporal association
of CVC-related infection and subsequent thrombosis. After
an episode of CVC-related infection, the risk of clinically
manifest thrombosis increased markedly (RR, 17.6). Be-
sides, our findings suggest that the absolute risk of develop-
ing a symptomatic thrombotic event increases with the
severity of CVC-related infection; a 57% thrombosis risk
was observed after an episode of CVC associated septice-
mia, versus 27% in patients with a local CVC infection.
Previously, a direct association of CVC-related infec-
tion and thrombosis has been suggested in autopsy studies.3
Reliable prospective data in which a direct relationship of
CVC-related infection and thrombosis has been reported
Table 3. Observed Cumulative Incidences of CVC-Associated Infections and the Absolute and
Relative Risks of Subsequent Clinically Manifest Thrombosis
Patients Risk of Thrombosis
No. % Absolute Risk (%) Relative Risk
No CVC-related infection 80 76.2 2.5
CVC-related infection*
Local CVC infection 11 10.5 27.3 10.9
Insertion-site 6
CVC colonization 1
Insertion site and CVC colonization 4
Systemic CVC infection 14 13.3 57.1 10.4
Overall 25 23.8 44.1 17.6
Abbreviation: CVC, central venous catheter.
For definitions of CVC related infection, see Table 1.
Fig 1. The risk of clinically manifest thrombosis based on at least two
surveillance central venous catheter lock fluid cultures.
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are scarce.4,5 In a study of critically ill patients (N  208),
the presence of subclinical thrombosis detected by routine
Doppler ultrasound performed at CVC removal was asso-
ciated with a three-fold increased rate of systemic CVC-
related septicemia.4 In hemato-oncology patients, only one
small study (n 42) has been performed, in which a direct
association of infection and thrombosis was reported.5 In
this study, daily screening using ultrasound for (subclinical)
thrombosis was used to estimate the risk of subsequent
CVC-related infection. From 13 patients with documented
subclinical thrombosis, CVC-related infection occurred in
12 (92%), whereas in 29 patients without thrombosis, the
number of infections was only two (7%).5 The main differ-
ence between our and these studies is that we have used
clinicallymanifest thrombosis as the primary end point and
that CVC-related infection was used as a parameter to pre-
dict symptomatic thrombotic events.
Based on our findings, as well as results from earlier
studies, it could be argued that the relationship of thrombosis
and infection is bi-directional. Thrombus formation, which is
commonly observed after catheterization,may play an impor-
tant role in the development of certain CVC-related infec-
tions.4,5,18,19 The composition of CVC-associated thrombi
consists of several proteins suchasfibrin,fibronectin, collagen,
laminin, and several types of immunoglobulins.20-22 Micro-
organisms, especially Staphylococcus aureus and certain types
of CoNS, easily adhere to thrombin sheaths, which could ex-
plain the clinical observation of a close association of CVC
infection and thrombosis.20-23 Besides, CVC-related infection
might induce an inflammatory response24 that could induce
or lead to further progression of excessive thrombus forma-
tion. Thrombosis and infectionmight also just be two separate
entities occurring simultaneously in patients who are severely
ill, but this hypothesis is not likely since themolecular basis of
thrombosis suggests a direct relationship.20-24 We can not,
however, exclude that thrombosis may be induced by a local
chemical phlebitis caused by antibiotics in patients treated for
CVC infection.
From a clinical point of view, surveillance cultures of
CVC lock fluidmay be valuable to assess the risk of clinically
manifest thrombosis in individual patients, particularly if
this risk assessment is based on serially determined cultures.
Such a strategy could allow early intervention in addition to
adequate antimicrobial therapy. Timely CVC removal at
the first sign of thrombosis or infection, or individualized
anticoagulant prophylaxis, may be beneficial. Such individ-
ualized risk assessment for clinically manifest thrombosis
might be an alternative for routine anticoagulant prophy-
laxis in patients with CVCs, especially after intensive che-
motherapy.25 However, this study was an observational
study, and whether early intervention would have changed
clinical outcome and whether such a strategy is cost effec-
tive is unknown and should be investigated. Although anti-
coagulant prophylaxis is recommended in consensus
guidelines, there is great reluctance among clinicians to
prescribe anticoagulant prophylaxis routinely because of
fear of bleeding complications and a low expected incidence
of thrombosis.25-27 In addition, since there seems to be a
strong association of infection and thrombosis, the use of
antibiotic impregnated CVCs may be of clinical benefit as
well. However, the outcome of intervention(s) based on
surveillance cultures is currently unknown, and this clearly
needs prospective evaluation before being routinely imple-
mented. Whether such intervention is based on a single or
multiple subsequent positive lock cultures is uncertain.
However, as in CVC-related infection, the accuracy indices
of surveillance cultures to predict clinicallymanifest throm-
bosis improved with more subsequent cultures (two or
more) that were positive for identical types and strains of
micro-organisms. Serially positive cultures are likely to re-
flect a more significant colonization of the CVC, or less
frequently, contamination as compared with a single posi-
tive surveillance culture.
In conclusion,wehave showna close associationofCVC-
related infectionwith thrombosis. The risk of developing clin-
ically manifest thrombosis increases substantially after an
episode of CVC-related infection (RR, 17.6) and is enhanced
by the severity of the infection. Routine culturing of CVC lock
fluid is clinically useful to monitor the risk of clinically mani-
fest thrombosis, which might allow early intervention. How-
ever, the outcome of such a strategy is currently unknown and
clearly needs to be explored prospectively.
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